A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
A phase 3 trial of Amivantamab, Cetuximab, Leucovorin (folinic acid) and Oxaliplatin in colorectal cancer, run by Janssen Research & Development, LLC, now recruiting.
Overview
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer is a phase 3 interventional study registered as NCT06662786 by Janssen Research & Development, LLC, with 1000 participants planned, started 2024-10-18 and due to reach its primary completion in 2028-12-15. Interventions recorded: Amivantamab, Cetuximab, 5-fluorouracil, Leucovorin calcium/Levoleucovorin, Oxaliplatin and Irinotecan Hydrochloride.
Similar pages
not linked directly; found by shared links- TrialA Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Shares Leucovorin (folinic acid), Amivantamab, Cetuximab, Johnson & Johnson and the tag pipeline.
- TrialStudy of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)
Shares Oxaliplatin, Cetuximab, Colorectal cancer and the tag pipeline.
- TrialEvaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer
Shares Leucovorin (folinic acid), Oxaliplatin and the tag pipeline.
- TrialA Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Shares Oxaliplatin, Cetuximab, Colorectal cancer and the tag pipeline.
- TrialIrinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer
Shares Leucovorin (folinic acid), Oxaliplatin and the tag pipeline.
- TrialEnhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
Shares Amivantamab, Johnson & Johnson and the tag pipeline.
- TrialA Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
Shares Amivantamab, Johnson & Johnson and the tag pipeline.
- TrialA Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
Shares Amivantamab, Johnson & Johnson and the tag pipeline.